Analyticon Discovery and Pharvaris extend their fruitful collaboration
BRAIN Group company Analyticon Discovery extends its collaboration with clinical-stage company Pharvaris, focused on bringing oral bradykinin-B2-receptor antagonist small molecules to patients.
Analyticon Discovery spezializes on natural product, drug discovery and development services. The Potsdam and USA based company is a leader in the design and development of chiral compound libraries and as such has earned a strong reputation over the years as a drug discovery CRO in a wide range of collaborations.
A key success story comes from its partnership with Pharvaris, a clinical-stage company specializing in the development of bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications.
Additional 18 months for joint R&D
Pharvaris has initiated Phase 2 studies of a bradykinin-B2-receptor antagonist for both on-demand and prophylactic treatment of HAE. With the extension of this collaboration for an additional 18 months, AnalytiCon Discovery and Pharvaris will continue to work together on the research and development of new bradykinin-B2-receptor antagonists to treat HAE and other conditions.
Jochen Knolle, Ph.D., chief scientific officer of Pharvaris, states: “We are thrilled that our collaboration with AnalytiCon Discovery has been extended. They have been our research partner from Pharvaris‘ inception and will continue to be instrumental in our drug discovery efforts on the development of new bradykinin-B2-receptor antagonists with the potential to treat additional indications.”
Christoph Gibson, Vice President Drug Discovery and Development at AnalytiCon Discovery, comments: "We are pleased to extend our fruitful collaboration with Pharvaris focussing on the characterization and development of new bradykinin-B2-receptor antagonists. This will open up new therapeutic indications for this highly attractive drug target."
"The collaboration between AnalytiCon Discovery and Pharvaris is an excellent example of a synergistic partnership between early-stage drug discovery and development experts to advance therapies efficiently in clinical development", Analyticon Discovery CEO Lutz Müller-Kuhrt, added.